hVIVO plc (AIM:HVO) (Euronext Growth:HVO), a specialist contract research organisation (CRO), announced on Tuesday that it has secured a contract worth GBP11.5m with an undisclosed top-tier pharmaceutical company to test an antiviral candidate using its Respiratory Syncytial Virus (RSV) Human Challenge Study Model.
The Phase 2a trial will evaluate safety, pharmacokinetics and antiviral activity, leveraging hVIVO's FluCamp volunteer recruitment arm and state-of-the-art facilities.
This repeat contract underscores the value of hVIVO's human challenge trials in accelerating drug development, the company said. RSV remains a significant global health burden, and hVIVO's model has been instrumental in advancing RSV drug and vaccine candidates.
hVIVO reaffirmed its FY 2024 revenue guidance of GBP62m, with full-year EBITDA margins at the upper end of market expectations.
(USD1=GBP0.78)
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses